166 related articles for article (PubMed ID: 38786147)
1. Meropenem Disposition in Neonatal and Pediatric Extracorporeal Membrane Oxygenation and Continuous Renal Replacement Therapy.
Pokorná P; Michaličková D; Tibboel D; Berner J
Antibiotics (Basel); 2024 May; 13(5):. PubMed ID: 38786147
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of fluconazole in critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study.
Novy E; Abdul-Aziz MH; Cheng V; Burrows F; Buscher H; Corley A; Diehl A; Gilder E; Levkovich BJ; McGuinness S; Ordonez J; Parke R; Parker S; Pellegrino V; Reynolds C; Rudham S; Wallis SC; Welch SA; Fraser JF; Shekar K; Roberts JA
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0120123. PubMed ID: 38063399
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation.
Lee JH; Lee DH; Kim JS; Jung WB; Heo W; Kim YK; Kim SH; No TH; Jo KM; Ko J; Lee HY; Jun KR; Choi HS; Jang JH; Jang HJ
Front Pharmacol; 2021; 12():768912. PubMed ID: 34790131
[No Abstract] [Full Text] [Related]
4. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
[TBL] [Abstract][Full Text] [Related]
5. Optimal Meropenem Dosing Regimens in Patients Undergoing Continuous Renal Replacement Therapy: Systematic Review and Monte Carlo Simulations.
Charoensareerat T; Chaijamorn W; Kerdnimith P; Kosumwisaisakul N; Teeranaew P; Rungkitwattanakul D; Boonpeng A; Srisawat N; Pattharachayakul S
Blood Purif; 2023; 52(6):503-515. PubMed ID: 37231811
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation.
Lee DH; Kim HS; Park S; Kim HI; Lee SH; Kim YK
Pharmaceutics; 2021 Nov; 13(11):. PubMed ID: 34834278
[TBL] [Abstract][Full Text] [Related]
8. Optimized Dosing Regimens of Meropenem in Septic Children Receiving Extracorporeal Life Support.
Wang Y; Chen W; Huang Y; Wang G; Li Z; Yan G; Chen C; Lu G
Front Pharmacol; 2021; 12():699191. PubMed ID: 34504424
[No Abstract] [Full Text] [Related]
9. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study.
Shekar K; Fraser JF; Taccone FS; Welch S; Wallis SC; Mullany DV; Lipman J; Roberts JA;
Crit Care; 2014 Dec; 18(6):565. PubMed ID: 25636084
[TBL] [Abstract][Full Text] [Related]
10. Meropenem pharmacokinetics during extracorporeal membrane oxygenation and continuous haemodialysis: a case report.
Saito J; Shoji K; Oho Y; Aoki S; Matsumoto S; Yoshida M; Nakamura H; Kaneko Y; Hayashi T; Yamatani A; Capparelli E; Miyairi I
J Glob Antimicrob Resist; 2020 Sep; 22():651-655. PubMed ID: 32417590
[TBL] [Abstract][Full Text] [Related]
11. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
[TBL] [Abstract][Full Text] [Related]
12. Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling.
Kang S; Yang S; Hahn J; Jang JY; Min KL; Wi J; Chang MJ
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431106
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Meta-Analysis and Dosing Recommendation for Meropenem in Critically Ill Patients Receiving Continuous Renal Replacement Therapy.
Peng Y; Cheng Z; Xie F
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0082222. PubMed ID: 36005753
[TBL] [Abstract][Full Text] [Related]
14. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
[TBL] [Abstract][Full Text] [Related]
16. NONMEM population pharmacokinetics and Monte Carlo dosing simulations of imipenem in critically ill patients with life-threatening severe infections during support with or without extracorporeal membrane oxygenation in an intensive care unit.
Jaruratanasirikul S; Boonpeng A; Nawakitrangsan M; Samaeng M
Pharmacotherapy; 2021 Jul; 41(7):572-597. PubMed ID: 34080708
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of meropenem in children with sepsis undergoing extracorporeal life support: A prospective observational study.
Wang Y; Li Z; Chen W; Yan G; Wang G; Lu G; Chen C
J Clin Pharm Ther; 2021 Jun; 46(3):754-761. PubMed ID: 33476064
[TBL] [Abstract][Full Text] [Related]
18. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Pediatric Patients.
Saito J; Shoji K; Oho Y; Kato H; Matsumoto S; Aoki S; Nakamura H; Ogawa T; Hasegawa M; Yamatani A; Miyairi I
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
